Verastem (VSTM) announced that the primary analysis of the Phase 2 RAMP 201 clinical trial was published online in the Journal of Clinical Oncology. The data reported in the publication showed that avutometinib plus defactinib demonstrated a confirmed overall response rate of 31% in all patients with recurrent low-grade serous ovarian cancer. The full manuscript will also appear in the print publication of JCO. The company will submit the RAMP 201 publication and the recent publication of the FRAME study to the National Comprehensive Cancer Network in support of its consideration of inclusion of the KRAS wild-type population evaluated in these trials in the NCCN Clinical Practice Guidelines in Oncology. Currently, the combination is listed as an NCCN Category 2A recommendation for the treatment of KRAS-mutated recurrent LGSOC, which is aligned with the FDA-approved indication.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Verastem’s Phase 3 Study on Avutometinib and Defactinib: A Potential Game-Changer for Ovarian Cancer Treatment
- Verastem’s Promising Phase 3 Study on Recurrent Ovarian Cancer
- Verastem announces Nature Medicine publication of FRAME results
- Verastem’s Promising Phase 3 Study on Avutometinib and Defactinib in Ovarian Cancer
- Verastem price target lowered to $12 from $16 at RBC Capital